About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases.
The Aegerion Pharmaceuticals, Inc. logo is available at
This press release contains forward-looking statements, including statements related to the closing of Aegerion's public offering of common stock and the anticipated use of proceeds from the offering, including references to the commercial launch of JUXTAPID in the United States, the possible approval of lomitapide in the European Union and other countries and the commencement of commercial activities in the European Union, if lomitapide is approved, and advancing the clinical development of lomitapide. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond Aegerion's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties with respect to the offering and anticipated use of proceeds include, among other factors: risks and uncertainties associated with market conditions and satisfaction of customary closing conditions related to the proposed offering, risks associated with Aegerion's ability to satisfy Aegerion's obligations to close the proposed offering and the risk that Aegerion will not use the proceeds from the offering in the manner contemplated. The risks and uncertainties with respect to the commercial launch of JUXTAPID in the United States, the possible approval of lomitapide in the European Union and other countries and the commencement of commercial activities in the European Union, if lomitapide is approved, and advancing the clinical development of lomitapide include: the risk that any delay or technical hurdle in completion of our validation work may delay availability of JUXTAPID for launch; the risk that regulatory authorities in the European Union or other countries outside the United States may not be satisfied with the efficacy or safety profile of lomitapide or our proposed risk management plan; the risk that we do not receive approval of lomitapide in the European Union or other countries outside the United States on a timely basis, or at all; the risk that technical hurdles may delay initiation of future clinical trials; the risks of unexpected results in our additional nonclinical or clinical development work with lomitapide; and the other risks inherent in drug development and the regulatory approval process. For additional disclosure regarding these and other risks, see the disclosure contained in Aegerion's public filings with the SEC (available on the SEC's website at
), including the "Risk Factors" section filed as an exhibit to Aegerion's Current Report on Form 8-K filed on January 10, 2013 and in the preliminary prospectus supplement and related prospectus relating to the proposed offering filed with the SEC on January 10, 2013. Aegerion undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
CONTACT: Aegerion Pharmaceuticals, Inc.
Michael Lawless, VP, IR
+ 1 (857) 242-5028